RBC Capital analyst Leonid Timashev raised the firm’s price target on Insmed (INSM) to $200 from $197 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed: Strong Brensocatib Launch but Pipeline and Payer Uncertainties Keep Risk‑Reward Balanced at Hold
- Unusually active option classes on open January 9th
- Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating
- Insmed Announces Strong 2025 Results and Pipeline Progress
- Insmed announces anticipated milestones for 2026